KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas

Journal of Pathology - Tập 202 Số 3 - Trang 375-381 - 2004
Chin‐Chen Pan1, Paul Chih‐Hsueh Chen1, Hung Chiang1
1Department of Pathology, National Yang-Ming University and Taipei Veterans General Hospital, Taiwan

Tóm tắt

AbstractKIT (CD117), a tyrosine kinase receptor, has not been widely studied in epithelial tumours. In a systematic immunohistochemical survey of KIT expression on tissue arrays incorporating 671 cases, it was found that thymic carcinomas frequently express KIT. Twenty‐two thymic carcinomas, 110 thymomas, and 16 non‐neoplastic thymus glands were retrieved for further analyses. Immunohistochemically, 19 (86%) thymic carcinomas revealed heterogeneous to diffuse membranous positivity, whereas no thymomas or normal thymus glands contained positive epithelial cells. Using reverse transcriptase‐polymerase chain reaction (RT‐PCR), c‐kit transcripts could be demonstrated in all immunohistochemically positive cases. PCR amplification and direct sequencing of the c‐kit juxtamembrane domains (exons 9 and 11) and tyrosine kinase domain (exons 13 and 17) were also performed on the thymic carcinomas but mutations were not found. Some non‐thymic epithelial tumours showed frequent KIT expression including adenoid cystic carcinomas of the salivary gland (100% positive), chromophobe renal cell carcinomas (94%), renal oncocytomas (67%), and neuroendocrine tumours (34%). Other carcinomas were infrequently immunoreactive for KIT. The findings of this study suggest that KIT is involved in the pathogenesis of thymic carcinomas. The overexpression of KIT in thymic carcinomas has potential diagnostic utility in differentiating these tumours from thymomas and carcinomas arising from other sites, which express KIT infrequently. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1053/hupa.2002.124124

Vandenbark GR, 1992, Cloning and structural analysis of the human c‐kit gene, Oncogene, 7, 1259

Holst VA, 1999, KIT protein expression and analysis of c‐kit gene mutation in adenoid cystic carcinoma, Mod Pathol, 12, 956

10.1016/S0304-3835(00)00387-6

10.1038/bjc.1996.236

Palmu S, 2002, Expression of C‐KIT and HER‐2 tyrosine kinase receptors in poor‐prognosis breast cancer, Anticancer Res, 22, 411

10.1016/S0169-5002(03)00034-5

Micke P, 2003, Characterization of c‐kit expression in small cell lung cancer: prognostic and therapeutic implications, Clin Cancer Res, 9, 188

10.1053/hupa.2002.129199

10.1002/(SICI)1097-0215(19980119)75:2<171::AID-IJC1>3.0.CO;2-R

Sekido Y, 1991, Preferential expression of c‐kit protooncogene transcripts in small cell lung cancer, Cancer Res, 51, 2416

10.1016/S0046-8177(98)90066-1

10.5858/2001-125-0146-EOCKCI

10.1007/978-3-642-60157-6_1

Shimosato Y, 1997, Atlas of Tumor Pathology: Tumors of the Mediastinum, 33

Ernst SI, 1998, KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors, Lab Invest, 78, 1633

10.1016/S0002-9440(10)65250-9

10.1016/S0002-9440(10)64623-8

10.1016/S0002-9440(10)64946-2

Rubin BP, 2001, KIT activation is a ubiquitous feature of gastrointestinal stromal tumors, Cancer Res, 61, 8118

10.1111/j.1349-7006.1999.tb00715.x

10.1111/j.1349-7006.2001.tb01121.x

Taniguchi M, 1999, Effect of c‐kit mutation on prognosis of gastrointestinal stromal tumors, Cancer Res, 59, 4297

10.1007/BF00193492

10.1309/EJ3RY45QCYPUKQG4

10.1309/AN4E2ETCJ4R6JJUY

10.1080/00313029800169056

10.1097/00000478-199708000-00008

10.1097/00000478-200005000-00014

10.1046/j.1365-2559.2003.01663.x

Di Como CJ, 2002, p63 expression profiles in human normal and tumor tissues, Clin Cancer Res, 8, 494

10.1007/s00428-003-0857-4

10.1046/j.1365-2559.2002.01328.x

10.1046/j.1365-2559.2002.01387.x

10.3109/10428199709114167

10.1111/j.1365-2141.1995.tb05364.x

10.1038/ng0396-312

10.1159/000237541

10.1053/hupa.2002.124122

10.1038/sj.onc.1206153